ACAD — Acadia Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $3.40bn
- $2.44bn
- $1.07bn
U.S. STOCKS ON THE MOVE-Marvell, US energy companies, copper miners
Soleno Therapeutics rises after rival's rare disease drug fails late-stage study
Acadia falls as rare disease therapy fails late-stage trial
U.S. STOCKS ON THE MOVE-Thor Industries, Mirion Technologies, ServiceNow
Acadia falls as rare disease therapy fails late-stage trial
Acadia Pharmaceuticals' rare disease therapy fails late-stage trial (updated)
Brief: Acadia Pharmaceuticals Announces Phase 3 COMPASS PWS Trial of Intranasal Carbetocin (ACP-101) for Hyperphagia in Prader-Willi Syndrome Did Not Meet Primary Endpoint
Acadia Pharmaceuticals' rare disease drug fails main goal in late-stage trial
Brief: Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Acadia Pharmaceuticals Appoints Konstantina Katcheves As Senior Vice President, Chief Business And Strategy Officer
Live Markets: Prader-Willi drug sparks Wall Street interest in multi-billion dollar market, Leerink says
Australia's Neuren Pharmaceuticals hits one-year high on DAYBUE sales jump
Acadia Pharmaceuticals Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: Acadia Pharmaceuticals Q2 EPS USD 0.16
Brief: Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. RESEARCH ROUNDUP- Aerovironment, Cisco, Dell Technologies
Brief: Acadia Pharmaceuticals expects To Deliver Over $1 Billion In Net Sales in FY2025
Brief: Acadia Pharmaceuticals reports inducement grants under Nasdaq listing rule
US appeals court confirms patent validity of Acadia's Parkinson's drug